Ichnos Gets Going With Almirall Deal, Multiple Myeloma Bispecifics Add Sheen
Executive Summary
Glenmark’s US-based innovation arm Ichnos delivers first licensing deal for IL-1RAP antagonist, while early data for a bispecific antibody demonstates promising activity in multiple in vitro and in vivo tumor models relative to daratumumab and magrolimab.
You may also be interested in...
Ichnos’ Early-Stage Myeloma Asset Designed To Avoid ‘Pitfalls’ Of Magrolimab
Glenmark’s innovation subsidiary, Ichnos, highlights encouraging early data for lead bispecific antibody assets and hopes to accelerate these via licensing and partnership deals.The US-based arm also points to the tough biopharma financing market where investors are no longer satisfied with just the “preclinical story”.
Almirall In The Market For Bolt-On Acquisitions
Much of Almirall's attention this year will be on submitting the potential atopic dermatitis blockbuster lebrikizumab in Europe but the Spanish firm is also looking at bringing in some other late-stage products.
Could CD47 Competitors Catch Up To Gilead After Magrolimab Hold?
Gilead isn’t giving details about the events behind the partial hold on magrolimab/Vidaza combination studies, but analysts suspect cytopenias are the culprit.